Richardson V J, Ryman B E, Jewkes R F, Jeyasingh K, Tattersall M N, Newlands E S, Kaye S B
Br J Cancer. 1979 Jul;40(1):35-43. doi: 10.1038/bjc.1979.138.
The possible use of liposomes (phospholipid vesicles) to direct cytotoxic drugs to tumours has led us to investigate the tissue localization of i.v. injected 99m-Tc-labelled liposomes in cancer patients. Twenty mg or 300 mg doses of liposomal lipid (7:2:1 molar ratio of phosphatidylcholine : cholesterol : phosphatidic acid) were used in a study of 13 patients with advanced cancer and one with polycythaemia rubra vera (PRV). In all cases except the patient with PRV the major site of uptake of the label was the liver and spleen. In the patient with PRV the liver uptake was greatly reduced and the major site of uptake was found in regions corresponding to marrow. With the exception of one patient with a primary hepatoma, there was no significant tumour uptake of the label.
利用脂质体（磷脂囊泡）将细胞毒性药物导向肿瘤的可能性促使我们研究静脉注射99m锝标记脂质体在癌症患者体内的组织定位。在一项针对13例晚期癌症患者和1例真性红细胞增多症（PRV）患者的研究中，使用了20mg或300mg剂量的脂质体脂质（磷脂酰胆碱：胆固醇：磷脂酸的摩尔比为7:2:1）。除PRV患者外，在所有病例中，标记物摄取的主要部位是肝脏和脾脏。在PRV患者中，肝脏摄取大大减少，摄取的主要部位位于与骨髓相对应的区域。除1例原发性肝癌患者外，标记物在肿瘤部位无明显摄取。
